Faizan Iftikhar, MD
Cardiology · McKinney, TXNPI 1417927393
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,436 of the $6,686 with a category attached, or 66.3%. 29 manufacturers reported payments, led by Eli Lilly at 24.1% of the total. Reporting peaked in 2024 at $2,097 and has fallen 90.1% since, to $208 in 2025.
Across 212 payments — averaging $31.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$2K
- Bayer$1K
- Merck$573
- Johnson & Johnson$432
- AstraZeneca$303
- Sanofi-aventis U.S. LLC$266
- plus $2K from 23 others
Across 666 payments — averaging $3063.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$1M
- Boehringer Ingelheim Pharma GmbH & Co.kg$308K
- American Regent$271K
- Eli Lilly$220K
- Esperion Therapeutics, Inc.$86K
- Astrazeneca UK Limited$33K
- plus $75K from 6 others
What the payments were for
- Travel & lodging$2,16532%
- Food & beverage$4,43666%
- Education$851%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 13 | $1,611 |
| Bayer | 10 | $1,244 |
| Merck | 30 | $573 |
| Johnson & Johnson | 23 | $432 |
| AstraZeneca | 15 | $303 |
| Sanofi-aventis U.S. LLC | 17 | $266 |
| Boston Scientific | 12 | $263 |
| Esperion Therapeutics, Inc. | 10 | $239 |
| Abbott | 10 | $230 |
| Medtronic(2 entities) | 4 | $178 |
| Pfizer | 10 | $158 |
| Amgen | 10 | $158 |
| Scpharmaceuticals Inc. | 7 | $147 |
| Novartis | 7 | $140 |
| Boehringer Ingelheim | 6 | $103 |
| Novo Nordisk | 4 | $91 |
| Regeneron Healthcare Solutions, Inc. | 4 | $87 |
| Siemens Medical Solutions USA, Inc. | 1 | $77 |
| Kowa Pharmaceuticals America, Inc. | 4 | $60 |
| Chiesi USA, Inc. | 2 | $53 |
| Lilly USA, LLC | 2 | $53 |
| Cardiovascular Systems Inc. | 3 | $51 |
| CSL Behring | 1 | $38 |
| E.r. Squibb & Sons, L.L.C. | 2 | $36 |
| Bridgebio Pharma, Inc. | 1 | $26 |
| Lexicon Pharmaceuticals, Inc. | 1 | $23 |
| Biotronik Inc. | 1 | $17 |
| Philips North America LLC | 1 | $14 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Reveal LINQ$106
How this compares
$6,686 in reported general payments places this provider in the 80th percentile of 33 cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 343 | $385,716 |
| XareltoRivaroxaban | 107 | $129,160 |
| JardianceEmpagliflozin | 67 | $52,007 |
| EntrestoSacubitril/Valsartan | 17 | $22,321 |
| Repatha SureclickEvolocumab | 16 | $14,871 |
| FarxigaDapagliflozin Propanediol | 15 | $10,294 |
| Metoprolol Succinate | 346 | $5,295 |
| Rosuvastatin Calcium | 310 | $5,143 |
| Flecainide Acetate | 105 | $3,650 |
| Olmesartan Medoxomil | 180 | $3,548 |
| Ezetimibe | 74 | $2,206 |
| Losartan Potassium | 165 | $2,192 |
| Amlodipine Besylate | 290 | $2,060 |
| ClopidogrelClopidogrel Bisulfate | 138 | $2,059 |
| Torsemide | 111 | $1,888 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $158 | $385,716343 claims |
| Johnson & JohnsonXarelto | $432 | $129,160107 claims |
| Boehringer IngelheimJardiance | $103 | $52,00767 claims |
| NovartisEntresto | $140 | $22,32117 claims |
| AstraZenecaFarxiga | $303 | $10,29415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 33 cardiology providers in Texas.
Other cardiology in McKinney
- Harvey SluskyWebster$26K
- Shiny MathewkuttyDallas$24K
- Sheikh AhmedHouston$14K
- Lane MillerCollege Station$11K
- Ramon TyHouston$11K
- Thieu NguyenHouston$5K
- Nadir AliWebster$3K
- Nadim ZaccaHouston$2K
- Adeniran AriyoDallas$1K
- Ralph NimchanLaredo$702
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.